NYSEAMERICAN:VNRX

VolitionRx - VNRX Stock Forecast, Price & News

$1.68

-0.04 (-2.33%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $1.65
▼
$1.74
50-Day Range: N/A
52-Week Range: $1.31
▼
$3.30

Volume: 70,486 shs
Average Volume: 153,273 shs
Market Capitalization: $97.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Institutional Ownership

Headlines

Short Interest

Social Media

VolitionRx MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 237.3% Upside
$5.67 Price Target
Short Interest: Healthy
1.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$409,500 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
VolitionRx has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.67, VolitionRx has a forecasted upside of 237.3% from its current price of $1.68.
Amount of Analyst Coverage
VolitionRx has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.39% of the float of VolitionRx has been sold short.
Short Interest Ratio / Days to Cover
VolitionRx has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in VolitionRx has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
VolitionRx does not currently pay a dividend.
Dividend Growth
VolitionRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VNRX.

N/A

News and Social Media Coverage

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $409,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
16.00% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.30% of the stock of VolitionRx is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for VolitionRx are expected to remain at ($0.58) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of VolitionRx is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of VolitionRx is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
VolitionRx has a P/B Ratio of 5.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About VolitionRx (NYSEAMERICAN:VNRX) Stock

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

March 21, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for VolitionRX (VNRX)

March 20, 2023 | benzinga.com

VolitionRX Stock (AMEX:VNRX), Guidance and Forecast

March 28, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast

March 19, 2023 | americanbankingnews.com

EF Hutton Acquisition Co. I Reaffirms "Buy" Rating for VolitionRx (NYSEAMERICAN:VNRX)

March 10, 2023 | finance.yahoo.com

VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update

March 6, 2023 | finance.yahoo.com

VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th

February 27, 2023 | finance.yahoo.com

VNRX: Nu.Q Vet Cancer Test Being Launched by Supply Agreement Partners Heska and IDEXX; 4.945 million Share Offering Completed to Help Fund Management’s Initiatives

February 22, 2023 | finance.yahoo.com

VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

February 17, 2023 | finance.yahoo.com

VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock

February 16, 2023 | finance.yahoo.com

Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation

January 8, 2023 | finance.yahoo.com

Volition Issues Business Review 2022

November 14, 2022 | finance.yahoo.com

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

November 14, 2022 | finance.yahoo.com

Volition Announces Clinical Research Study with Oncovet

November 10, 2022 | finance.yahoo.com

Volition to Participate in a Lung Cancer Screening Study in France

October 20, 2022 | benzinga.com

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test - VolitionRX (AMEX:VNRX) - Benzinga

October 20, 2022 | nasdaq.com

VolitionRx Signs Global Supply Deal For Nu.Q Vet Cancer Test - Nasdaq

October 20, 2022 | finance.yahoo.com

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test

October 11, 2022 | finance.yahoo.com

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo Finance

September 12, 2022 | proactiveinvestors.com

NA Proactive news snapshot: Unrivaled Brands, Steppe Gold, Quantum eMotion, First Mining Gold, Co-Diagnostics, Doré Copper Mining, Todos Medical UPDTE... - Proactive Investors USA

September 12, 2022 | globenewswire.com

VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th - GlobeNewswire

August 16, 2022 | finance.yahoo.com

Volition Appoints Mickie Henshall as an Independent Director

August 11, 2022 | greenwichtime.com

VolitionRX: Q2 Earnings Snapshot - Greenwich Time

August 11, 2022 | proactiveinvestors.com

VolitionRX announces 2nd quarter financials as company look to accelerate growth - Proactive Investors USA

August 11, 2022 | seekingalpha.com

VolitionRX Q2 2022 Earnings Preview (NYSE:VNRX) - Seeking Alpha

August 10, 2022 | proactiveinvestors.com

NA Proactive news snapshot: Banxa Holdings, Xeris Biopharma, VolitionRx Limited, TRACON Pharmaceuticals, Etruscus Resources UPDATE ... - Proactive Investors USA

August 10, 2022 | seekingalpha.com

VolitionRX reports Q2 results (NYSE:VNRX) - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Company Calendar

Last Earnings: 11/10/2021
Today: 3/28/2023
Next Earnings (Estimated): 3/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:VNRX
Previous Symbol: NYSEMKT:VNRX
CUSIP: N/A
CIK: N/A
Web: www.volitionrx.com
Phone: (646) 650-1351
Fax: 65 32 8172 5651
Employees: 65
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.67
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +233.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,820,000.00
Net Margins: -15,452.74%
Pretax Margin: -15,607.46%
Return on Equity: -350.45%
Return on Assets: -116.26%

Debt

Debt-to-Equity Ratio: 0.94
Current Ratio: 1.04
Quick Ratio: 1.04

Sales & Book Value

Annual Sales: $90,000.00
Price / Sales: 1,098.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.33 per share
Price / Book: 5.15

Miscellaneous

Outstanding Shares: 58,140,000
Free Float: 48,838,000
Market Cap: $98.84 million
Optionable: Not Optionable
Beta: 1.73

Key Executives

Cameron John Reynolds
President, Chief Executive Officer & Director

Gaetan Michel
Chief Operating Officer

Terig Hughes
Chief Financial Officer & Treasurer

Jacob Vincent Micallef
Chief Scientific Officer

Terry Kelly
Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNRX Stock - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.
What is VolitionRx's stock price forecast for 2023?: 3 brokerages have issued 12-month price targets for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.
When is VolitionRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our VNRX earnings forecast.
How were VolitionRx's earnings last quarter?: VolitionRx Limited (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. VolitionRx had a negative net margin of 15,452.74% and a negative trailing twelve-month return on equity of 350.45%.
What other stocks do shareholders of VolitionRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Protalix BioTherapeutics (PLX), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).

What is VolitionRx's stock symbol?: VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."
Who are VolitionRx's major shareholders?: VolitionRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Lagoda Investment Management L.P. (6.55%), Morgan Stanley (0.44%), Cowen Prime Advisors LLC (0.31%), Spectrum Asset Management Inc. NB CA (0.10%), Cerity Partners LLC (0.07%) and Susquehanna International Group LLP (0.00%). Insiders that own company stock include Cameron John Reynolds, Guy Archibald Innes, Jacob Vincent Micallef, Jason Bradley Md Terrell, Kim Nguyen, Martin Charles Faulkes, Nicholas Plummer and Salvatore Thomas Butera.
View institutional ownership trends.
How do I buy shares of VolitionRx?: Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is VolitionRx's stock price today?: One share of VNRX stock can currently be purchased for approximately $1.70.
How much money does VolitionRx make?: VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $98.84 million and generates $90,000.00 in revenue each year. The medical research company earns $-26,820,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.
How can I contact VolitionRx?: VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.

This page (NYSEAMERICAN:VNRX) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

VolitionRx - VNRX Stock Forecast, Price & News

VolitionRx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Company Ownership

Earnings and Valuation

About VolitionRx (NYSEAMERICAN:VNRX) Stock

VNRX Stock News Headlines

VNRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VNRX Stock - Frequently Asked Questions

Overall MarketRank^™